OncoMatch/Clinical Trials/NCT05880043
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
Is NCT05880043 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including GIC-102 and GIC-102 for advanced solid tumors.
Treatment: GIC-102 · GIC-102 — This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: pre-conditioning allowed
Received chemotherapy other than pre-conditioning within 4 weeks
Cannot have received: allogeneic cell therapy
Have received allogeneic cell therapy within 6 months
Cannot have received: autologous stem cell therapy
autologous stem cell therapy within 4 weeks
Cannot have received: allogeneic tissue/solid organ transplant
previously received an allogeneic tissue/solid organ transplant
Cannot have received: investigational drug or device
administered other investigational drug or applied other investigational medical device within 4 weeks
Lab requirements
Blood counts
acceptable hematological function
Kidney function
acceptable kidney function
Liver function
acceptable liver function
Acceptable hematological function, kidney, and liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify